Guardant Health (NASDAQ:GH) Shares Gap Up to $16.07

Guardant Health, Inc. (NASDAQ:GH)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $16.07, but opened at $16.78. Guardant Health shares last traded at $16.96, with a volume of 663,410 shares trading hands.

Analyst Ratings Changes

A number of analysts have commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Piper Sandler decreased their price target on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday, February 26th. The Goldman Sachs Group decreased their price target on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, April 15th. Guggenheim restated a “neutral” rating on shares of Guardant Health in a research note on Friday, April 5th. Finally, Canaccord Genuity Group reduced their target price on shares of Guardant Health from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and a consensus target price of $40.40.

Guardant Health Stock Down 1.4 %

The stock’s fifty day moving average is $19.10 and its two-hundred day moving average is $23.11. The company has a current ratio of 6.54, a quick ratio of 6.24 and a debt-to-equity ratio of 7.18. The company has a market capitalization of $2.11 billion, a PE ratio of -4.05 and a beta of 0.87.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). The company had revenue of $155.05 million during the quarter, compared to analysts’ expectations of $151.71 million. Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. As a group, analysts predict that Guardant Health, Inc. will post -3.49 EPS for the current year.

Insider Buying and Selling

In related news, insider Kumud Kalia purchased 2,187 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were bought at an average cost of $17.82 per share, with a total value of $38,972.34. Following the acquisition, the insider now owns 12,722 shares of the company’s stock, valued at $226,706.04. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 6.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Guardant Health

Several institutional investors have recently added to or reduced their stakes in the business. Oppenheimer Asset Management Inc. lifted its holdings in Guardant Health by 2.8% during the third quarter. Oppenheimer Asset Management Inc. now owns 16,854 shares of the company’s stock valued at $500,000 after purchasing an additional 453 shares during the last quarter. Amalgamated Bank increased its position in shares of Guardant Health by 3.2% during the third quarter. Amalgamated Bank now owns 17,058 shares of the company’s stock valued at $506,000 after buying an additional 521 shares during the period. CWM LLC increased its position in shares of Guardant Health by 137.1% during the third quarter. CWM LLC now owns 984 shares of the company’s stock valued at $29,000 after buying an additional 569 shares during the period. Van ECK Associates Corp increased its position in shares of Guardant Health by 29.4% during the fourth quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock valued at $73,000 after buying an additional 614 shares during the period. Finally, State Board of Administration of Florida Retirement System increased its position in shares of Guardant Health by 2.1% during the third quarter. State Board of Administration of Florida Retirement System now owns 32,238 shares of the company’s stock valued at $956,000 after buying an additional 670 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.